Purple Biotech (PPBT) files updated corporate presentation for investors

Rhea-AI Filing Summary

Purple Biotech Ltd. filed a Form 6-K as a foreign private issuer to furnish an updated corporate presentation titled “Purple Biotech Corporate presentation September 2025.” The presentation is attached as Exhibit 99.1. The company states that this Form 6-K, including all exhibits, is incorporated by reference into multiple existing registration statements on Forms S-8, F-3 and F-1, with specified SEC file numbers. This means the updated presentation now forms part of those registration statements from the date this report is submitted, unless later filings supersede it.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of September 2025

Commission File Number: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. 

Form 20-F ☒        Form 40-F ☐

Purple Biotech

On September 15, 2025, Purple Biotech Ltd. (the “Company” or the “Registrant”) issued an updated Company presentation, “Purple Biotech Corporate presentation September 2025”, which is attached hereto as Exhibit 99.1.

Exhibit
99.1		Purple Biotech Corporate presentation September 2025

Incorporation by Reference

This Report on Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission on December 27, 2019 (Registration file number 333-235729), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107) and the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on December 8, 2022 (Registration file number 333-268710), the Registrant’s Registration Statement on Form F-1, as amended, originally filed with the Securities and Exchange Commission on October 30, 2023 (Registration file number 333-275216) and the Registrant’s Registration Statement on Form F-1, filed with the Securities and Exchange Commission on July 22, 2024 (Registration file number 333-280947), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

September 15, 2025	PURPLE BIOTECH LTD.
	By:	/s/ Gil Efron
		Gil Efron
		Chief Executive Officer

2

FAQ

What did Purple Biotech (PPBT) report in this Form 6-K?

Purple Biotech Ltd. reported that it issued an updated company presentation titled “Purple Biotech Corporate presentation September 2025,” which is furnished as Exhibit 99.1 to the Form 6-K.

When did Purple Biotech issue the updated corporate presentation?

Purple Biotech issued the updated corporate presentation on September 15, 2025, as stated in the Form 6-K.

What is Exhibit 99.1 in Purple Biotech’s Form 6-K?

Exhibit 99.1 is the document titled “Purple Biotech Corporate presentation September 2025”, which is the updated corporate presentation furnished with the Form 6-K.

How is this Form 6-K used in Purple Biotech’s existing SEC registration statements?

The Form 6-K states that it, including all exhibits, is incorporated by reference into multiple existing registration statements on Forms S-8, F-3 and F-1, identified by their SEC registration file numbers.

Does the Form 6-K specify Purple Biotech’s status with respect to annual reports?

The document notes that the registrant files annual reports under cover of Form 20-F, indicating its reporting framework as a foreign private issuer.

Who signed the Purple Biotech Form 6-K for the updated presentation?

The Form 6-K was signed on behalf of Purple Biotech Ltd. by Gil Efron, the company’s Chief Executive Officer, dated September 15, 2025.